ADVERTISEMENT

Natco Pharma Q2 Results Review - Strong Quarter, Pipeline Build-Up Underway: ICICI Securities

The brokerage maintains Hold rating on the stock with target price of Rs 1,430 on 20x FY26E EPS of base biz and net present value value of Rs 250 for limited competition opportunities in U.S.

<div class="paragraphs"><p>Natco Pharma Ltd.'s manufacturing plant in Dehradun. (Source: Company website)</p></div>
Natco Pharma Ltd.'s manufacturing plant in Dehradun. (Source: Company website)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit